Cite
HARVARD Citation
Hart, C. et al. (n.d.). Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial. Journal of the European Academy of Dermatology and Venereology. pp. e119-e121. [Online].